Search hospitals > Michigan > Ann Arbor

Saint Joseph Mercy Hospital

Claim this profile
Ann Arbor, Michigan 48105
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Recurrence
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
492 reported clinical trials
10 medical researchers
Photo of Saint Joseph Mercy Hospital in Ann ArborPhoto of Saint Joseph Mercy Hospital in Ann ArborPhoto of Saint Joseph Mercy Hospital in Ann Arbor

Summary

Saint Joseph Mercy Hospital is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Lung Cancer, Recurrence, Breast Cancer, Adenocarcinoma and other specialties. Saint Joseph Mercy Hospital is involved with conducting 492 clinical trials across 573 conditions. There are 10 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.

Area of expertise

1Cancer
Global Leader
Saint Joseph Mercy Hospital has run 176 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Saint Joseph Mercy Hospital has run 69 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Saint Joseph Mercy Hospital

Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Prostate Cancer
Bladder Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Multiple Myeloma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Joseph Mercy Hospital?
Saint Joseph Mercy Hospital is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Lung Cancer, Recurrence, Breast Cancer, Adenocarcinoma and other specialties. Saint Joseph Mercy Hospital is involved with conducting 492 clinical trials across 573 conditions. There are 10 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Where is Saint Joseph Mercy Hospital located?
To reach St. Joseph Mercy Hospital in Ann Arbor, Michigan, take I-94 to exit 180B and head north on Washtenaw Avenue. Turn right onto Huron Parkway, then left onto East Huron River Drive. The hospital is located at 5301 East Huron River Drive, Ann Arbor, MI 48106.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Saint Joseph Mercy Hospital, please reach out to the Patient Accounts department at (877) 727-9190. They offer support with medical bills, payment options, financial assistance applications, and insurance benefits. Detailed information on the hospital's financial assistance policy is available on their website.
What insurance does Saint Joseph Mercy Hospital accept?
Saint Joseph Mercy Hospital accepts a variety of health insurance types, including commercial, Medicare, and Medicaid, from many local and national carriers. Before scheduling visits, confirm coverage and restrictions with your insurance provider, as some services may need to be scheduled at specific network locations to avoid denial of coverage. For specific insurance plans accepted and coverage questions, contact your insurance company directly or call the member services number on your insurance card.
What awards or recognition has Saint Joseph Mercy Hospital received?
Saint Joseph Mercy Hospital in Ann Arbor, Michigan, was recognized as the No. 1 teaching hospital in the U.S. by Fortune/IBM Watson Health in 2020. It has been named one of the nation's 100 Top Hospitals by IBM Watson Health ten times, including in 2019. The hospital's health system received a $19.3 million grant in 2019 to lead the Michigan Cancer Research Consortium, one of the largest federal grants Trinity Health has ever received.